Sanofi Shares Drop On Trial Setback For Breast Cancer Pill
By Ludwig Burger (Reuters) -Sanofi’s shares slid 5% on Monday after a drug candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker’s drug development prowess. Results from the Phase II AMEERA-3 clinical trial, keenly awaited by Sanofi investors,…
